Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment
Fig 5
Multiplex enzyme-linked immunosorbent assay of four key cytokines.
At each time point 4 weeks post-treatment initiation where lungs were harvested for CFU counting, 150μl of lung homogenate was set aside for cytokine analysis. At week 4, animals in the TV Ad35+, NC-V, NC-T4 and PC groups were identical prior to randomization. Immediately following randomization at week 4, animals in the TV Ad35+ group received immunotherapy with 1010 viral particles of Ad35-TBS and animals in the NC-V group received 1010 empty Ad35 vector which were both boosted at week 8. At week 16, animals in the TV Ad35+ groups were randomized into TV Ad26+ and TV Ad26- and received 1010 viral particles of Ad26-TBS and Ad26 empty vector, respectively. All animals were administered anti-TB therapy except the NC-IU and NC-UU control groups as depicted in Fig 1. Graph depicts the mean cytokine value with standard deviation (n = 4 at each time point for all groups).